Market Cap 885.83M
Revenue (ttm) 719.89M
Net Income (ttm) 98.09M
EPS (ttm) N/A
PE Ratio 8.38
Forward PE 8.52
Profit Margin 13.63%
Debt to Equity Ratio 0.79
Volume 377,700
Avg Vol 600,374
Day's Range N/A - N/A
Shares Out 44.09M
Stochastic %K 78%
Beta 0.91
Analysts Hold
Price Target $22.83

Company Profile

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a dry nasal spray used in an emergency for the treatment of severe hypoglycemia; Primatene MIST, an epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Glucagon for injection emergency kit; Enoxaparin, an injectable f...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 909 980 9484
Address:
11570 6th Street, Rancho Cucamonga, United States
EquityInvest
EquityInvest Jun. 11 at 12:04 AM
Does Xeris’ Strong Q1 2026 Rebound And Raised Outlook Change The Bull Case For XERS? - Simply Wall St $AMPH https://stocks.apple.com/AtiZI-jFhRx-yP_8Q3LJvBw
0 · Reply
MarketBeat
MarketBeat Jun. 10 at 11:10 PM
https://marketbeat.com/a/8706100/ $AMPH Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth
0 · Reply
tradeordie24
tradeordie24 Jun. 9 at 6:08 PM
$AMPH higher highs and higher lows push to $22+ tomorrow
1 · Reply
tradeordie24
tradeordie24 Jun. 9 at 2:34 PM
$AMPH $22 inbound
1 · Reply
tradeordie24
tradeordie24 Jun. 8 at 2:50 PM
$AMPH $22 soon
0 · Reply
tradeordie24
tradeordie24 Jun. 8 at 11:47 AM
$AMPH breakout to $22?
0 · Reply
EquityInvest
EquityInvest Jun. 5 at 2:49 PM
$AMPH i’m not letting this thing get above 20 
0 · Reply
MarketBeat
MarketBeat Jun. 4 at 4:03 AM
https://marketbeat.com/a/8691230/ $AMPH Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
0 · Reply
EquityInvest
EquityInvest Jun. 3 at 2:03 PM
$AMPH $AMPH $AMPH In April 2026, the FDA classified the International Medication Systems (IMS) manufacturing facility in South El Monte, California—a subsidiary of Amphastar Pharmaceuticals—as Official Action Indicated (OAI). This classification follows a routine FDA facility inspection in December 2025 and indicates that the agency found objectionable conditions and recommends regulatory or administrative action.
0 · Reply
EquityInvest
EquityInvest May. 29 at 7:08 PM
$AMPH $AMPH In April 2026, the FDA classified the International Medication Systems (IMS) manufacturing facility in South El Monte, California—a subsidiary of Amphastar Pharmaceuticals—as Official Action Indicated (OAI). This classification follows a routine FDA facility inspection in December 2025 and indicates that the agency found objectionable conditions and recommends regulatory or administrative action.
0 · Reply
Latest News on AMPH
Amphastar Pharmaceuticals Slides: FY 2026

Jun 3, 2026, 4:55 PM EDT - 11 days ago

Amphastar Pharmaceuticals Slides: FY 2026


Amphastar price target lowered to $20 from $23 at Barclays

2026-06-03T09:43:26.000Z - 12 days ago

Amphastar price target lowered to $20 from $23 at Barclays


Amphastar Pharmaceuticals Transcript: AGM 2026

Jun 1, 2026, 2:30 PM EDT - 13 days ago

Amphastar Pharmaceuticals Transcript: AGM 2026


Amphastar Pharmaceuticals Slides: FY 2026

May 13, 2026, 6:00 PM EDT - 4 weeks ago

Amphastar Pharmaceuticals Slides: FY 2026


Amphastar downgraded to Hold from Buy at Needham

2026-05-08T18:05:47.000Z - 5 weeks ago

Amphastar downgraded to Hold from Buy at Needham


Amphastar Pharmaceuticals Earnings Call Transcript: Q1 2026

May 7, 2026, 5:00 PM EDT - 5 weeks ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q1 2026


Amphastar Pharmaceuticals Earnings release: Q1 2026

May 7, 2026, 5:00 PM EDT - 5 weeks ago

Amphastar Pharmaceuticals Earnings release: Q1 2026


Amphastar Pharmaceuticals Slides: Q1 2026

May 7, 2026, 5:00 PM EDT - 5 weeks ago

Amphastar Pharmaceuticals Slides: Q1 2026


Amphastar Pharmaceuticals Quarterly report: Q1 2026

May 7, 2026, 5:00 PM EDT - 5 weeks ago

Amphastar Pharmaceuticals Quarterly report: Q1 2026


Amphastar downgraded to Hold from Buy at Jefferies

2026-04-20T20:41:17.000Z - 7 weeks ago

Amphastar downgraded to Hold from Buy at Jefferies


Amphastar Pharmaceuticals Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Amphastar Pharmaceuticals Proxy statement: Proxy filing


Amphastar Pharmaceuticals Proxy statement: Proxy filing

Apr 13, 2026, 8:00 AM EDT - 2 months ago

Amphastar Pharmaceuticals Proxy statement: Proxy filing


Amphastar price target lowered to $23 from $30 at Barclays

2026-04-08T09:05:42.000Z - 2 months ago

Amphastar price target lowered to $23 from $30 at Barclays


Amphastar price target lowered to $30 from $34 at Wells Fargo

2026-02-27T13:00:20.000Z - 3 months ago

Amphastar price target lowered to $30 from $34 at Wells Fargo


Amphastar Pharmaceuticals Earnings Call Transcript: Q4 2025

Feb 26, 2026, 5:00 PM EST - 3 months ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q4 2025


Amphastar Pharmaceuticals Annual report: Q4 2025

Feb 26, 2026, 5:00 PM EST - 3 months ago

Amphastar Pharmaceuticals Annual report: Q4 2025


Amphastar Pharmaceuticals Earnings release: Q4 2025

Feb 26, 2026, 5:00 PM EST - 3 months ago

Amphastar Pharmaceuticals Earnings release: Q4 2025


Amphastar Pharmaceuticals Slides: Q4 2025

Feb 26, 2026, 5:00 PM EST - 3 months ago

Amphastar Pharmaceuticals Slides: Q4 2025


Amphastar Announces FDA Approval for Ipratropium Bromide HFA

Feb 24, 2026, 6:00 AM EST - 3 months ago

Amphastar Announces FDA Approval for Ipratropium Bromide HFA


Amphastar price target lowered to $30 from $31 at BofA

2026-01-07T14:30:15.000Z - 5 months ago

Amphastar price target lowered to $30 from $31 at BofA


Amphastar announces FDA approval for teriparatide injection

2025-12-15T11:11:28.000Z - 6 months ago

Amphastar announces FDA approval for teriparatide injection


Amphastar Announces FDA Approval for Teriparatide Injection

Dec 15, 2025, 6:00 AM EST - 6 months ago

Amphastar Announces FDA Approval for Teriparatide Injection


Amphastar initiated with an Equal Weight at Barclays

2025-12-08T21:32:03.000Z - 6 months ago

Amphastar initiated with an Equal Weight at Barclays


Amphastar Pharmaceuticals Slides: FY 2025

Nov 19, 2025, 10:30 AM EST - 7 months ago

Amphastar Pharmaceuticals Slides: FY 2025


Amphastar Pharmaceuticals Earnings Call Transcript: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q3 2025


Amphastar Pharmaceuticals Quarterly report: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Amphastar Pharmaceuticals Quarterly report: Q3 2025


Amphastar Pharmaceuticals Earnings release: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Amphastar Pharmaceuticals Earnings release: Q3 2025


Amphastar Pharmaceuticals Slides: Q3 2025

Nov 6, 2025, 5:00 PM EST - 7 months ago

Amphastar Pharmaceuticals Slides: Q3 2025


Amphastar price target lowered to $31 from $32 at BofA

2025-10-09T12:35:56.000Z - 8 months ago

Amphastar price target lowered to $31 from $32 at BofA


Amphastar Pharmaceuticals Slides: FY 2025

Sep 3, 2025, 12:45 PM EDT - 10 months ago

Amphastar Pharmaceuticals Slides: FY 2025


Amphastar price target raised to $32 from $28 at BofA

2025-08-26T10:35:09.000Z - 10 months ago

Amphastar price target raised to $32 from $28 at BofA


Amphastar announced FDA approval of iron sucrose injection

2025-08-12T10:50:52.000Z - 10 months ago

Amphastar announced FDA approval of iron sucrose injection


Needham upgrades Amphastar on valuation post AMP-002 approval

2025-08-12T10:50:46.000Z - 10 months ago

Needham upgrades Amphastar on valuation post AMP-002 approval

VTRS


Amphastar upgraded to Buy from Hold at Needham

2025-08-12T10:45:20.000Z - 10 months ago

Amphastar upgraded to Buy from Hold at Needham


Amphastar Announces FDA Approval for Iron Sucrose Injection, USP

Aug 11, 2025, 6:00 AM EDT - 11 months ago

Amphastar Announces FDA Approval for Iron Sucrose Injection, USP


Amphastar Pharmaceuticals Earnings Call Transcript: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q2 2025


Amphastar Pharmaceuticals Quarterly report: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

Amphastar Pharmaceuticals Quarterly report: Q2 2025


Amphastar Pharmaceuticals Earnings release: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

Amphastar Pharmaceuticals Earnings release: Q2 2025


Amphastar Pharmaceuticals Slides: Q2 2025

Aug 7, 2025, 5:00 PM EDT - 11 months ago

Amphastar Pharmaceuticals Slides: Q2 2025


Amphastar Pharmaceuticals Slides: FY 2025

Jun 5, 2025, 2:00 PM EDT - 1 year ago

Amphastar Pharmaceuticals Slides: FY 2025


Amphastar Pharmaceuticals Slides: FY 2025

May 14, 2025, 4:40 PM EDT - 1 year ago

Amphastar Pharmaceuticals Slides: FY 2025


Amphastar Pharmaceuticals Earnings Call Transcript: Q1 2025

May 7, 2025, 5:00 PM EDT - 1 year ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q1 2025


Amphastar Pharmaceuticals Quarterly report: Q1 2025

May 7, 2025, 5:00 PM EDT - 1 year ago

Amphastar Pharmaceuticals Quarterly report: Q1 2025


Amphastar Pharmaceuticals Earnings release: Q1 2025

May 7, 2025, 5:00 PM EDT - 1 year ago

Amphastar Pharmaceuticals Earnings release: Q1 2025


Amphastar Pharmaceuticals Slides: Q1 2025

May 7, 2025, 5:00 PM EDT - 1 year ago

Amphastar Pharmaceuticals Slides: Q1 2025


Amphastar Pharmaceuticals Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Amphastar Pharmaceuticals Proxy statement: Proxy Filing


Amphastar Pharmaceuticals Proxy statement: Proxy Filing

Apr 14, 2025, 8:00 AM EDT - 1 year ago

Amphastar Pharmaceuticals Proxy statement: Proxy Filing


Amphastar Pharmaceuticals Proxy statement: Proxy Filing

Apr 2, 2025, 8:00 AM EDT - 1 year ago

Amphastar Pharmaceuticals Proxy statement: Proxy Filing


Amphastar Pharmaceuticals Earnings Call Transcript: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q4 2024


Amphastar Pharmaceuticals Annual report: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Annual report: Q4 2024


Amphastar Pharmaceuticals Earnings release: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Earnings release: Q4 2024


Amphastar Pharmaceuticals Slides: Q4 2024

Feb 27, 2025, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Slides: Q4 2024


Amphastar Pharmaceuticals Slides: FY 2025

Jan 15, 2025, 2:15 PM EST - 1 year ago

Amphastar Pharmaceuticals Slides: FY 2025


Amphastar Pharmaceuticals Slides: FY 2024

Nov 20, 2024, 10:30 AM EST - 1 year ago

Amphastar Pharmaceuticals Slides: FY 2024


Amphastar Pharmaceuticals Earnings Call Transcript: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q3 2024


Amphastar Pharmaceuticals Quarterly report: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Quarterly report: Q3 2024


Amphastar Pharmaceuticals Earnings release: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Earnings release: Q3 2024


Amphastar Pharmaceuticals Slides: Q3 2024

Nov 6, 2024, 5:00 PM EST - 1 year ago

Amphastar Pharmaceuticals Slides: Q3 2024


Amphastar Pharmaceuticals Slides: FY 2024

Sep 5, 2024, 10:15 AM EDT - 1 year ago

Amphastar Pharmaceuticals Slides: FY 2024


Amphastar Pharmaceuticals Earnings Call Transcript: Q2 2024

Aug 7, 2024, 5:00 PM EDT - 2 years ago

Amphastar Pharmaceuticals Earnings Call Transcript: Q2 2024


Amphastar Pharmaceuticals Quarterly report: Q2 2024

Aug 7, 2024, 5:00 PM EDT - 2 years ago

Amphastar Pharmaceuticals Quarterly report: Q2 2024


Amphastar Pharmaceuticals Earnings release: Q2 2024

Aug 7, 2024, 5:00 PM EDT - 2 years ago

Amphastar Pharmaceuticals Earnings release: Q2 2024


Amphastar Pharmaceuticals Slides: Q2 2024

Aug 7, 2024, 5:00 PM EDT - 2 years ago

Amphastar Pharmaceuticals Slides: Q2 2024


EquityInvest
EquityInvest Jun. 11 at 12:04 AM
Does Xeris’ Strong Q1 2026 Rebound And Raised Outlook Change The Bull Case For XERS? - Simply Wall St $AMPH https://stocks.apple.com/AtiZI-jFhRx-yP_8Q3LJvBw
0 · Reply
MarketBeat
MarketBeat Jun. 10 at 11:10 PM
https://marketbeat.com/a/8706100/ $AMPH Amphastar Pharmaceuticals Pivots to Proprietary Drugs, Biosimilars for Growth
0 · Reply
tradeordie24
tradeordie24 Jun. 9 at 6:08 PM
$AMPH higher highs and higher lows push to $22+ tomorrow
1 · Reply
tradeordie24
tradeordie24 Jun. 9 at 2:34 PM
$AMPH $22 inbound
1 · Reply
tradeordie24
tradeordie24 Jun. 8 at 2:50 PM
$AMPH $22 soon
0 · Reply
tradeordie24
tradeordie24 Jun. 8 at 11:47 AM
$AMPH breakout to $22?
0 · Reply
EquityInvest
EquityInvest Jun. 5 at 2:49 PM
$AMPH i’m not letting this thing get above 20 
0 · Reply
MarketBeat
MarketBeat Jun. 4 at 4:03 AM
https://marketbeat.com/a/8691230/ $AMPH Amphastar Pharmaceuticals Sees Generic Atrovent Fueling 2026 Growth Despite BAQSIMI Drag
0 · Reply
EquityInvest
EquityInvest Jun. 3 at 2:03 PM
$AMPH $AMPH $AMPH In April 2026, the FDA classified the International Medication Systems (IMS) manufacturing facility in South El Monte, California—a subsidiary of Amphastar Pharmaceuticals—as Official Action Indicated (OAI). This classification follows a routine FDA facility inspection in December 2025 and indicates that the agency found objectionable conditions and recommends regulatory or administrative action.
0 · Reply
EquityInvest
EquityInvest May. 29 at 7:08 PM
$AMPH $AMPH In April 2026, the FDA classified the International Medication Systems (IMS) manufacturing facility in South El Monte, California—a subsidiary of Amphastar Pharmaceuticals—as Official Action Indicated (OAI). This classification follows a routine FDA facility inspection in December 2025 and indicates that the agency found objectionable conditions and recommends regulatory or administrative action.
0 · Reply
ghfisch
ghfisch May. 22 at 2:08 PM
$AMPH sentiment right now is at 98 out of 100.. I think that's the highest I've ever seen for any stock
1 · Reply
EquityInvest
EquityInvest May. 20 at 2:03 AM
$AMPH In April 2026, the FDA classified the International Medication Systems (IMS) manufacturing facility in South El Monte, California—a subsidiary of Amphastar Pharmaceuticals—as Official Action Indicated (OAI). This classification follows a routine FDA facility inspection in December 2025 and indicates that the agency found objectionable conditions and recommends regulatory or administrative action.
0 · Reply
NVDAMillionaire
NVDAMillionaire May. 19 at 11:45 PM
$AMPH Brilliant piece that captures AMPH's situation perfectly. So if you want to update your understanding of AMPH or get to know AMPH better, this is essential reading. https://everyticker.com/quote/AMPH/analysis/amphastar-s-manufacturing-moat-faces-its-moment-of-truth-can-proprietary-pipeline-offset-generic-erosion-nasdaq-amph
0 · Reply
Arcides
Arcides May. 15 at 4:25 PM
$AMPH new 5 years low for this former IBD 50 stock...
0 · Reply
MarketBeat
MarketBeat May. 14 at 6:06 AM
https://marketbeat.com/a/8653243/ $AMPH Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook
0 · Reply
Estimize
Estimize May. 12 at 8:00 PM
Wall St is expecting 0.71 EPS for $AMPH Q2 [Reporting 08/10 AMC] http://www.estimize.com/intro/amph?chart=historical&metric_name=eps&utm_co
0 · Reply
EquityInvest
EquityInvest May. 8 at 2:43 PM
$AMPH I love this company.  shorting before earnings never fails 🤑😂😂💪
0 · Reply
JRZMike
JRZMike May. 8 at 10:56 AM
$AMPH what a shit show this stock has become
0 · Reply
StocktwitsEarnings
StocktwitsEarnings May. 7 at 8:30 PM
$AMPH Q1 '26 Earnings Results & Recap • Reported GAAP EPS of $0.14 down -73.58% YoY • Reported revenue of $171.17M up 0.38% YoY
0 · Reply
SuperGreenToday
SuperGreenToday Apr. 23 at 9:39 PM
$AMPH Share Price: $21.01 Contract Selected: Sep 18, 2026 $22.5 Calls Buy Zone: $0.09 – $0.11 Target Zone: $0.15 – $0.18 Potential Upside: 66% ROI Time to Expiration: 147 Days | Updates via https://fxcapta.com/stockinfo/
0 · Reply
briefingcom
briefingcom Apr. 21 at 12:28 PM
$AMPH: Amphastar Pharmaceuticals (-1.1%) downgraded to Hold from Buy at Jefferies, tgt $22 https://www.briefing.com/calendars/updown?Filter=downgrades&utm_campaign=updown&utm_medium=social&utm_source=st&utm_content=link
0 · Reply
NewsTrader_perform4nce
NewsTrader_perform4nce Apr. 16 at 1:25 PM
The next Peptide rally at $AMPH?? $HIMS is up 23% since my post last night. Another stock that could also benefit from a peptide boom (so far, the stock has barely reacted) could be $AMPH Amphastar Pharmaceuticals They develop, manufacture, and sell their own medications and peptides. I've added it to my portfolio. Moreover, it's fundamentally quite attractive with a price-to-sales ratio of under 1.5 and a price-to-earnings ratio of 10
0 · Reply